Opinion|Videos|August 13, 2024

Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

Experts give an overview of the ASCO 2024 data.

Video content above is prompted by the following question:

The phase 2 CORE-001 trial investigated a new treatment combination of intravesical cretostimogene grenadenorepvec with pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC. Before we review the trial background and results presented at the ASCO 2024 Annual Meeting, can you introduce cretostimogene and describe its mechanism of action?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME